Dr. med. Christian Taverna kommentiert Myeloma Highlights vom ASH2016


1   Michele Cavo, et al. Intensification Therapy with Bortezomib-Melphalan-Prednison Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial) Oral Abstract 6739; Session 731; ASH 2016 (https://ash.confex.com/ash/2016/webprogram/ Paper91284.html)

2  Pieter Sonneveld, et al. Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial) Oral Abstract 242; Session 653; ASH 2016 (https://ash.confex.com/ash/2016/webprogram/Paper91988.html)

3 Thierry Facon ,et al. Final Analysis of Overall Survival from the First Trial. Oral Abstract 241; Session 653; ASH 2016 (https://ash.confex.com/ash/2016/webprogram/Paper91328.html)

4 Asher A. Chanan-Khan, et al. Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor Poster Abstract 3313; Session 653; ASH 2016 (https://ash.confex.com/ash/2016/webprogram/Paper96799.html)

5   Philippe Moreau, et al. Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux. Oral Abstract 489; Session 653; ASH 2016 (https://ash.confex.com/ash/2016/webprogram/Paper93492.html)

6 Christoph Driessen, et al. The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13) Oral Abstract 487; Session 653; ASH 2016  (https://ash.confex.com/ash/2016/webprogram/Paper96473.html)


Prof. Dr. med. Christoph Renner kommentiert Lymphoma Highlights vom ASH2016

1 Wyndham H. Wilson, et al. Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. Oral Abstract 469; Session 626; ASH 2016 (https://ash.confex.com/ash/2016/webprogram/Paper97112.html)

2 Steven H. Swerdlow, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016 127:2375-2390; doi: https://doi.org/10.1182/blood-2016-01-643569

3 Umberto Vitolo, et al. Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA). Oral Abstract 470; Session 626; ASH 2016 (https://ash.confex.com/ash/2016/webprogram/Paper96159.html)

4 Christiane Pott, et al. Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study. Oral Abstract 613; Session 623; ASH 2016  (https://ash.confex.com/ash/2016/webprogram/Paper96473.html)

5 Bruce D. Cheson, et al. Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study. Abstract 615; Session 623; ASH 2016 (https://ash.confex.com/ash/2016/webprogram/Paper91544.html)

6 Ramon Garcia-Sanz, et al. Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Oral Abstract 1109; Session 624; ASH 2016 (https://ash.confex.com/ash/2016/webprogram/Paper95020.html)